Search

You searched for "nAMD"

520 results found
Retina journal front cover image.

Systemic pharmacology of intravitreal anti-VEGF

1 April 2018 | | EYE - Vitreo-Retinal
This study aimed to evaluate and compare serum drug concentrations and plasma free-VEGF concentrations in patients with AMD, DME, or RVO receiving intravitreal injections of aflibercept, bevacizumab or ranibizumab. This prospective study enrolled patients from several offices of a single...
Retina journal front cover image.

Macular atrophy with aflibercept

1 October 2018 | | EYE - Vitreo-Retinal
The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...
Seminars in Ophthalmology journal cover image

The effects of anti-VEGF therapy for NvAMD on retinal vasculature

4 August 2021 | | EYE - Vitreo-Retinal | aflibercept, foveal avascular zone, neovascular age-related macular degeneration, ranibizumab, retinal vessel density
This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...
Journal of Neuro-Ophthalmology cover image.

Exploring the potential of neurodegenerative disease screening within age-related eye disease research

3 August 2023 | | EYE - Neuro-ophthalmology
The authors recruited healthy controls aged between 60 and 75-years-old, previously enrolled into a registry as patients following cataract surgery without age-related macular degeneration (AMD). Exclusion criteria included dense cataract, retinal disease, ocular inflammatory disease, moderate glaucoma, optic neuropathy, cancer,...

Heidelberg Engineering joins the Collaborative Community on Ophthalmic Innovation (CCOI) through EssilorLuxottica’s Vision Architect membership

26 January 2026 | Contracts & Distributors, Company Profiles
Heidelberg Engineering announced that it is joining the Collaborative Community on Ophthalmic Innovation (CCOI) as part of its parent company EssilorLuxottica’s Vision Architect membership – CCOI’s highest level of industry participation. CCOI is a public–private forum that convenes patients, clinicians,...

The blue-light hazard – is it true?

1 February 2019 | | EYE - Vitreo-Retinal, EYE - General
Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: The blue-light hazard – is it true? Blue light is part of the visible optical spectrum...

What's trending Jun/Jul 2023

5 June 2023 | | EYE - General
A round-up of the eye-related hot topics that have been trending on social media over the last few weeks. #whoopigoldberg #presbyopia #bionic Whoopi Goldberg made a name for herself in blockbusters such as the Oscar-winning Ghost and Sister Act. She...

Technology in ophthalmology – a promising future and what we need to know about the regulations

1 October 2017 | | EYE - Cataract, EYE - Refractive, EYE - Cornea, EYE - Glaucoma, EYE - Imaging, EYE - Orbit, EYE - Vitreo-Retinal, EYE - General
Undoubtedly, ophthalmology is one of the greatest sources of inspiration for technological progress in medicine. Thus far, we have seen remarkable advancements in the technology used by ophthalmologists across all subspecialties. From simplifying common procedures, to treating previously incurable conditions,...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

1 February 2015 | | EYE - Vitreo-Retinal
The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...

Simulating the visual impairment symptoms of age-related macular degeneration in virtual reality

5 June 2023 | | EYE - Vitreo-Retinal
A new virtual reality application visually simulates age-related macular degeneration and demonstrates its progression over time including some Charles Bonnet syndrome hallucinations. Introduction Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries with the prevalence of...

Initiatives in macular service provision

1 December 2015 | | EYE - Vitreo-Retinal
A report from Monitor in October 2015 identifies good practices that will realise most of the potential productivity gain in elective care available to NHS hospitals. These include: stratifying patients by risk and creating low-complexity pathways for lower-risk patients (tailoring...

In conversation with Robert MacLaren

2 December 2019 | EYE - Vitreo-Retinal, EYE - General
Professor Robert MacLaren gave the Keeler Lecture at the Royal College of Ophthalmologists Annual Meeting in May 2019 on gene therapy for retinitis pigmentosa. We caught up with him afterwards to find out more. What are the key messages of...